Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Mouse Models of Cancer Study02:43

Mouse Models of Cancer Study

6.8K
Mice have long served as models for studying human biology and pathology because of their phylogenetic and physiological similarity with humans. They are also easy to maintain and breed in the laboratory, and hence, many inbred strains are now available for research. Studies on mice have contributed immeasurably to our understanding of cancer biology.
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
6.8K
Mouse Models of Cancer Study02:43

Mouse Models of Cancer Study

2.6K
2.6K
Cancer Prevention02:59

Cancer Prevention

8.7K
Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
8.7K
Cancer Prevention02:59

Cancer Prevention

3.1K
3.1K
Cancer02:18

Cancer

56.1K
Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
56.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A taxonomy of work-related outcomes in cancer survivors to advance systematic assessments in research and practice.

Journal of the National Cancer Institute·2026
Same author

Illustrative Integration of Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Data in Dose-Cohort Review for a Phase I Clinical Trial.

Research square·2026
Same author

Patient-reported outcomes as early indicators of recurrence, disease progression, and survival via machine learning in breast cancer.

NPJ breast cancer·2026
Same author

Real-world clinical outcomes of lenvatinib+pembrolizumab for the treatment of patients with non-microsatellite instability-high/mismatch repair proficient recurrent or advanced endometrial cancer following prior systemic therapy in the United States.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2026
Same author

Developing a Novel Values Elicitation Measure for Clinical Use in Older Adults with Hematologic Malignancies: Values-HM.

MDM policy & practice·2026
Same author

Benefits of Electronic Symptom Monitoring During Cancer Treatment by Age, Sex, Race, and Education (Alliance AFT-39).

JCO oncology practice·2026

Related Experiment Video

Updated: Apr 14, 2026

Author Spotlight: Advancing Prostate Cancer Research Through Improved Tissue Sampling and Biobanking
07:34

Author Spotlight: Advancing Prostate Cancer Research Through Improved Tissue Sampling and Biobanking

Published on: November 17, 2023

1.4K

The project data sphere initiative: accelerating cancer research by sharing data.

Angela K Green1, Katherine E Reeder-Hayes2, Robert W Corty2

  • 1UNC Lineberger Comprehensive Cancer Center, School of Medicine, Division of Hematology and Oncology, Eshelman School of Pharmacy, Division of Pharmaceutical Outcomes and Policy, and Gillings School of Global Public Health, Department of Health Policy and Management, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA Angela.Green@unchealth.unc.edu.

The Oncologist
|April 17, 2015
PubMed
Summary

Project Data Sphere (PDS) offers a platform for sharing deidentified cancer clinical trial data to accelerate research and improve patient outcomes. This initiative aims to foster collaboration and efficiency in oncology drug development.

Keywords:
Comparative effectiveness researchData sharingProject Data SphereProstate cancer

More Related Videos

Generation of Comprehensive Thoracic Oncology Database - Tool for Translational Research
11:18

Generation of Comprehensive Thoracic Oncology Database - Tool for Translational Research

Published on: January 22, 2011

16.6K
Use of Magnetic Resonance Imaging and Biopsy Data to Guide Sampling Procedures for Prostate Cancer Biobanking
05:49

Use of Magnetic Resonance Imaging and Biopsy Data to Guide Sampling Procedures for Prostate Cancer Biobanking

Published on: October 10, 2019

7.1K

Related Experiment Videos

Last Updated: Apr 14, 2026

Author Spotlight: Advancing Prostate Cancer Research Through Improved Tissue Sampling and Biobanking
07:34

Author Spotlight: Advancing Prostate Cancer Research Through Improved Tissue Sampling and Biobanking

Published on: November 17, 2023

1.4K
Generation of Comprehensive Thoracic Oncology Database - Tool for Translational Research
11:18

Generation of Comprehensive Thoracic Oncology Database - Tool for Translational Research

Published on: January 22, 2011

16.6K
Use of Magnetic Resonance Imaging and Biopsy Data to Guide Sampling Procedures for Prostate Cancer Biobanking
05:49

Use of Magnetic Resonance Imaging and Biopsy Data to Guide Sampling Procedures for Prostate Cancer Biobanking

Published on: October 10, 2019

7.1K

Area of Science:

  • Oncology
  • Clinical Trials
  • Data Science
  • Bioinformatics

Background:

  • Cancer research requires new paradigms to accelerate therapeutic development due to modest declines in mortality rates.
  • Phase III clinical trials generate substantial patient-level data, including control arm data, which can be valuable for further research.
  • Existing data-sharing efforts aim to make individual patient-level clinical trial data accessible to the scientific community.

Purpose of the Study:

  • To introduce the Project Data Sphere (PDS) initiative as a novel data-sharing platform for cancer research.
  • To highlight the potential of PDS to transform cancer research and improve patient outcomes through collaborative data analysis.
  • To address concerns regarding data privacy and intellectual property through deidentification and varied data access models.

Main Methods:

  • PDS is an independent initiative facilitating voluntary sharing, integration, and analysis of comparator arm data from historical cancer clinical trials.
  • It provides a neutral, broad-access platform for industry and academia to share raw, deidentified, late-phase oncology clinical trial data.
  • Data providers upload deidentified data after signing a data sharing agreement, with integrated analytic tools provided by SAS Institute.

Main Results:

  • As of October 2014, PDS contained data from 14 cancer clinical trials, encompassing 9,000 subjects, with plans to expand significantly.
  • The platform enables pooled analysis of data from multiple sponsors to create comprehensive cohorts.
  • A "Prostate Cancer Challenge" is underway, encouraging the research community to use PDS data to address key questions in metastatic castration-resistant prostate cancer.

Conclusions:

  • Access to large, late-phase cancer trial datasets via platforms like PDS can significantly enhance research efficiency and accelerate progress in cancer care.
  • PDS offers unique opportunities for research in neglected areas and for constructing complex models requiring extensive data.
  • The full potential of PDS will be realized with broader availability of diverse tumor types and a larger number of datasets.